Pacer Advisors’s Abeona Therapeutics ABEO Stock Holding History

Pacer Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-233	Closed	-$75K	–	531
2018 Q3	$75K	Buy	+233	New	+$82.7K	﹤0.01%	1119

Other funds holding ABEO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Pacer Advisors's ABEO Position: Q4 2018 in Review

Pacer Advisors sold out of Abeona Therapeutics (ABEO) in Q4 2018, closing a stake of 233 shares — an estimated $75K sold.

Pacer Advisors first reported a position in ABEO in Q3 2018 and held it in 1 quarter. The position peaked at $75K in Q3 2018. 99 funds tracked by Wall St. Rank hold ABEO as of Q4 2018.

Pacer Advisors reported no remaining Abeona Therapeutics position as of Q4 2018 after selling out during the quarter.
Pacer Advisors sold 233 Abeona Therapeutics shares in Q4 2018, an estimated $75K.
Pacer Advisors first reported a position in Abeona Therapeutics in Q3 2018 and held it in 1 quarter.
Pacer Advisors's Abeona Therapeutics position peaked at $75K in Q3 2018.
99 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2018.

Based on Pacer Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.